Loading stock data…
$9.84-0.89 (-8.29%)
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Arcturus Therapeutics Holdings Inc. in the Healthcare sector is trading at $9.84 with a market capitalization of $450M. Wall Street consensus targets $23.80 (10 analysts), implying a +141.9% move over the next 12 months. The stock is currently 45% below its 52-week high of $17.96, remaining 10.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $880,000↑ | $610,000↓ | $3.08M↓ | $14.15M↓ | $24.51M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.55M↑ | -$28.93M↑ | -$31.31M↓ | -$16.51M↓ | -$11.62M |
| Net Income | -$23.79M↑ | -$26.96M↑ | -$29.08M↓ | -$13.45M↓ | -$9.18M |
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...